Companies /Healthcare
Merck & Co Inc
NYSE: MRK Drug Manufacturers - General
$148.87
▲ $2.54 (+1.73%) today
Markets open · 10:47am ET

Merck & (MRK) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
100%
EPS beat rate
+14.56%
Avg. EPS surprise
Consecutive EPS beats
MRK vs Market · 30-day return after each reportMRKS&P 500
0%+7%+14%−2.8%+8.1%Q1 25+0.7%+2.2%Q2 25+17.1%+0.3%Q3 25−0.0%−2.5%Q4 25+5.9%+5.7%Q1 26+19.0%+0.2%Q2 26
0%+7%+14%Q1 25Q3 25Q1 26
MRK EPS Trend · estimate vs actualEstimateActual
$0$2$2.14$2.22Q1 25$2.03$2.13Q2 25$2.35$2.58Q3 25$2.01$2.04Q4 25$-1.47$-1.28Q1 26$-0.26$-0.13Q2 26$2.09$2.49Q3 26
$0$2Q1 25Q3 25Q1 26Q3 26
MRK Revenue Trend · estimate vs actualEstimateActual
$0$5.0B$10.0B$15.0B$15.3B$15.5BQ1 25$15.9B$15.8BQ2 25$17.0B$17.3BQ3 25$16.2B$16.4BQ4 25$15.8B$16.3BQ1 26$16.4B$16.6BQ2 26$17.3B$18.1BQ3 26
$0$5.0B$10.0B$15.0BQ1 25Q3 25Q1 26Q3 26

How Often Does Merck & Beat Earnings Estimates?

Merck & beat EPS estimates in 7 of its last 7 reported quarters, and has beaten 7 quarters in a row.

MRK quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 GAAP and non-GAAP EPS include a one-time charge of $0.12 per share ($400 million R&D charge) related to a global license agreement with SciBrunch. Prior-year Q3 included a $0.10 per share charge for a milestone payment to LaNova. $2.49 est. $2.09 +18.87% $18.1B est. $17.3B +4.25%
Q2 2026 Includes a charge of $2.31 per share for the acquisition of Terns Pharmaceuticals, for which no tax benefit was recorded. $-0.13 est. $-0.26 +49.53% $16.6B est. $16.4B +1.47%
Q1 2026 $-1.28 est. $-1.47 +13.15% $16.3B est. $15.8B +2.77%
Q4 2025 $2.04 est. $2.01 +1.47% $16.4B est. $16.2B +1.20%
Q3 2025 $2.58 est. $2.35 +9.85% $17.3B est. $17.0B +1.76%
Q2 2025 $2.13 est. $2.03 +5.04% $15.8B est. $15.9B −0.42%
Q1 2025 $2.22 est. $2.14 +3.98% $15.5B est. $15.3B +1.29%

Figures from SEC filings and company reports. Not investment advice.